Entresto (sacubitril/valsartan) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

		MEMBER'S FIRS	「NAME:	
Instructions: Please fill out that is important for the rev contained in this form is Pr	view (e.g., chart notes or la	b data, to support	oly. Attach any additional documentation the authorization request). Information URGENT	
MEMBER INFORMATION	N			
LAST NAME:		FIRST NAME:		
PHONE NUMBER:		DATE OF BIRTH:		
STREET ADDRESS:				
CITY:		STATE:	ZIP CODE:	
PATIENT INSURANCE ID NUMBER:				
IF YOU ARE NOT THE PA	ATIENT OR THE PRESCR ZATION FORM WITH THIS	IBER, YOU WILL S REQUEST WHIC): ALLERGIES: NEED TO SUBMIT A PHI CH CAN BE FOUND AT THE	
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):AUTHORIZED REPRESENTATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMA	ATION			
LAST NAME:		FIDOT NAME.		
LAGI WANE.		FIRST NAME:		
PRESCRIBER SPECIAL	TY:	EMAIL ADDR		
	TY:		ESS:	
PRESCRIBER SPECIAL	TY:	EMAIL ADDR	ESS:	
PRESCRIBER SPECIAL NPI NUMBER:	TY:	EMAIL ADDR	ESS:	
PRESCRIBER SPECIAL NPI NUMBER: PHONE NUMBER:	TY:	EMAIL ADDR	ESS:	
PRESCRIBER SPECIAL NPI NUMBER: PHONE NUMBER: STREET ADDRESS:		EMAIL ADDR DEA NUMBER FAX NUMBER STATE:	ESS: R:	
PRESCRIBER SPECIAL NPI NUMBER: PHONE NUMBER: STREET ADDRESS: CITY: REQUESTER (if different	nt than prescriber):	EMAIL ADDR DEA NUMBER FAX NUMBER STATE: OFFICE CON	ESS: R: ZIP CODE:	
PRESCRIBER SPECIAL NPI NUMBER: PHONE NUMBER: STREET ADDRESS: CITY: REQUESTER (if different		EMAIL ADDR DEA NUMBER FAX NUMBER STATE: OFFICE CON	ESS: R: ZIP CODE:	
PRESCRIBER SPECIAL NPI NUMBER: PHONE NUMBER: STREET ADDRESS: CITY: REQUESTER (if different	nt than prescriber):	EMAIL ADDR DEA NUMBER FAX NUMBER STATE: OFFICE CON	ESS: R: ZIP CODE: TACT PERSON: QUANTITY:	
PRESCRIBER SPECIAL NPI NUMBER: PHONE NUMBER: STREET ADDRESS: CITY: REQUESTER (if different MEDICATION OR MEDIC MEDICATION NAME:	ot than prescriber): CAL DISPENSING INFORI FREQUENCY: RENEWAL IF R	EMAIL ADDR DEA NUMBER FAX NUMBER STATE: OFFICE CONT MATION LENGTH OF THERAPY/RE	ESS: R: ZIP CODE: TACT PERSON: QUANTITY:	



Entresto (sacubitril/valsartan) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST N	NAME:
1. HAS THE PATIENT TRIED ANY	OTHER MEDICATIONS FOR THIS	CONDITION?
YES (if yes, complete below)	NO	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
Systolic left ventricular dysfur	oction(HErEE)	
Diastolic dysfunction (HFpEF)		
1 = ' ' ' '		
Other diagnosis:	ICD-10 Code(s):	
3. REQUIRED CLINICAL INFORMATO SUPPORT A PRIOR AUTHORI	ATION: PLEASE PROVIDE ALL REI	LEVANT CLINICAL INFORMATION
	in combination with a clinical trial	? ☐ Yes ☐ No
For all diagnoses, please answer		
Is patient NYHA Class II, III, or IV		
is patient NTHA class II, III, or IV	E LIES LINO	
For Systolic left ventricular dysfu Does the patient have an ejection documentation.	<u>inction(HFrEF):</u> a fraction of 49% or less? □ Yes □ l	No <i>Please submit chart</i>
	th Systolic left ventricular dysfunction(s) for chronic heart failure?	
	nction(HFpEF), please answer the for a fraction of 50% or greater? □ Yes	
hypertrophy(LVH) (i.e. septal or p	uctural heart damage, including eit posterior wall thickness >1.1cm, or 9ml/m2)? □ Yes □ No <i>Pl</i> ease s <i>ubr</i>	left atrial(LA) enlargement (i.e.
Does patient have a BMI >40kgm2	2? Yes No Please submit chai	rt documentation.
therapy for their COPD, chronic r	nary disease including severe COP nebulizer therapy or chronic oral st Please submit chart documentatio	eroid therapy for treatment of
Does patient have severe <u>pulmor</u> No <i>Please submit chart documen</i>	nary disease including primary pul Intation.	monary hypertension? □ Yes □
	dition or diagnosis causing patient alve regurgitation causing the hea	



Entresto (sacubitril/valsartan) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:			
cardiomyopathy, infiltrative cardiomyopathy, d Yes No Please submit chart documentation.	rug induced cardiomyopathy, or viral myocarditis? □			
Has patient been using a diuretic for at least 30 documentation.	days? Yes No Please submit chart			
If hospitalized for heart failure within past 9 months of starting Entresto, is patient's NT-proBNP >200pg/ml? □ Yes □No Please submit chart documentation. If not hospitalized in past 9 months for heart failure, is patient's NT-proBNP >300pg/ml? □ Yes □ No Please submit chart documentation. If patient has atrial fibrillation, is patient's NT-proBNP > 900pg/ml? □ Yes □ No Please submit chart documentation.				
IF NT-proBNP not available, does patient have a BNP >100pg/ml without kidney failure? □ Yes □ No Please submit chart documentation.				
If NT-proBNP not available and patient has kidney failure, does patient have a BNP>200pg/ml? □ Yes □ No <i>Please submit chart documentation.</i>				
If NT-proBNP not available and patient has Atrial fibrillation(AF), does patient have a BNP >150pg/ml? Yes No Please submit chart documentation.				
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?				
Please note: Not all drugs/diagnosis are covered required information is received.	on all plans. This request may be denied unless all			
	s true and accurate to the best of my knowledge. I Group or its designees may perform a routine audit and the accuracy of the information reported on this form.			
Prescriber Signature or Electronic I.D. Verificat	ion: Date:			
	ompanying this transmission contain confidential health			
	the intended recipient, you are hereby notified that any			
disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly				
prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.				
	RM TO: 800-424-7640			

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811

Phone: 877-228-7909

